It’s a rotten time to be raising money. And for small biotechnology companies most of which have little or no revenue and are dependent on investor capital to stay afloat times are tough indeed. According to the Wall Street Journal 120 of the 360 publicly traded biotech firms have less than 6 months of cash on hand. And while this isn’t an entirely foreign position for industry upstarts to be in the challenging fundraising environment means many of these companies could go under. The business of developing experimental drugs procedures and devices has always been one of high risk and ...